ESMO 2014

Sequencing Abiraterone Acetate, Cabazitaxel, and Enzalutamide in Post-Docetaxel mCRPC: Exploiting Efficacy and Avoiding Cross-Resistance

Conference Correspondent - ESMO 2014 - Prostate Cancer

Abiraterone acetate, enzalutamide, and cabazitaxel have been shown to prolong overall survival in patients with metastatic castrate-resistant prostate cancer (mCRPC) who have progressive disease or have become intolerant to docetaxel, but the optimal sequencing of these agents remains unclear. In [ Read More ]

Adding Docetaxel to ADT Significantly Improves Survival versus ADT Alone in Patients with High-Volume Metastatic Prostate Cancer

Conference Correspondent - ESMO 2014 - Prostate Cancer

The standard of care for prostate cancer is androgen-deprivation therapy (ADT), and although most patients respond to this treatment, many progress to metastatic castration-resistant prostate cancer (mCRPC). Specifically, patients with high-volume disease have poorer outcomes than those with lower volume [ Read More ]

Androgen Receptor and CYP17A1 Copy Number Variations as Predictors of Outcomes in Patients with Metastatic Prostate Cancer Receiving Abiraterone

Conference Correspondent - ESMO 2014 - Prostate Cancer

Abiraterone acetate is a potent inhibitor of cytochrome P450 17 alpha-hydrolase (CYP17A1), causing a decrease in the synthesis of testosterone and a demonstrated overall survival (OS) advantage in patients with metastatic castration-resistant prostate cancer (mCRPC; Ryan CI, et al. N [ Read More ]